Evofem Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned hereunto duly authorized.
| EVOFEM BIOSCIENCES, INC. | ||
| March 24, 2025 | By: | /s/ Saundra Pelletier |
|---|---|---|
| Name: | Saundra Pelletier | |
| Title: | President, Chief Executive Officer and Interim Chairperson of the Board |
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Saundra Pelletier | President, Chief Executive Officer and Interim Chairperson of the Board | March 24, 2025 |
| Saundra Pelletier | (Principal Executive Officer) | |
| /s/ Ivy Zhang | Chief Financial Officer and Secretary | March 24, 2025 |
| Ivy Zhang | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Kim P. Kamdar, Ph.D. | Director | March 24, 2025 |
| Kim P. Kamdar, Ph.D. | ||
| /s/ Tony O’Brien | Director | March 24, 2025 |
| Tony O’Brien | ||
| /s/ Colin Rutherford | Director | March 24, 2025 |
| Colin Rutherford | ||
| /s/ Lisa Rarick | Director | March 24, 2025 |
| Lisa Rarick | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.